Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term squamous-cell carcinoma. Found 45 abstracts

no pagination
Shaikh T, Meyer JE, Horwitz EM. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. Surg Oncol Clin N Am. 2017 Jul;26(3):405-29.   PMCID: REVIEW
Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecologic Oncology. 2012 Dec;127(3):451-5.   PMCID: NIHMS342821
Konski A, Li TY, Christensen M, Cheng JD, Yu JQ, Crawford K, Haluszka O, Tokar J, Scott W, Meropol NJ, Cohen SJ, Maurer A, Freedman GM. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in F-18-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiotherapy and Oncology. 2012 Jul;104(1):72-7.   PMCID: PMC3389132
Swisher SG, Winter KA, Komaki RU, Ajani JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A PHASE II STUDY OF A PACLITAXEL-BASED CHEMORADIATION REGIMEN WITH SELECTIVE SURGICAL SALVAGE FOR RESECTABLE LOCOREGIONALLY ADVANCED ESOPHAGEAL CANCER: INITIAL REPORTING OF RTOG 0246. International Journal of Radiation Oncology Biology Physics. 2012 Apr;82(5):1967-72.   PMCID: *
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current treatment options in oncology. 2012 Sep;13(3):390-402.   PMCID: Not NIH funded
Ajani JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, Meron Aj VP. Esophageal and Esophagogastric Junction Cancers. Journal of the National Comprehensive Cancer Network. 2011 Aug;9(8):830-+.   PMCID: not NIH funded
Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WN. Occult Primary Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2011 Dec;9(12):1358-95.   PMCID: not NIH funded
Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 May;121(2):303-8.   PMCID: PMC3081894
Fogh SE, Yu A, Kubicek GJ, Scott W, Mitchell E, Rosato EL, Berger AC. DO ELDERLY PATIENTS EXPERIENCE INCREASED PERIOPERATIVE OR POSTOPERATIVE MORBIDITY OR MORTALITY WHEN GIVEN NEOADJUVANT CHEMORADIATION BEFORE ESOPHAGECTOMY?. International Journal of Radiation Oncology Biology Physics. 2011 Aug;80(5):1372-6.   PMCID: not NIH funded
McDonald MW, Lawson J, Garg MK, Quon H, Ridge JA, Saba N, Salama JK, Smith RV, Yeung AR, Yom SS, Beitler JJ, Expert Panel Radiation O. ACR APPROPRIATENESS CRITERIA (R) RETREATMENT OF RECURRENT HEAD AND NECK CANCER AFTER PRIOR DEFINITIVE RADIATION. International Journal of Radiation Oncology Biology Physics. 2011 Aug;80(5):1292-8.   PMCID: not NIH funded
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu JM, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology. 2010 Jan;11(1):21-8.   PMCID: not NIH funded
Lee JJ, Natsuizaka M, Ohashi S, Wong GS, Takaoka M, Michaylira CZ, Budo D, Tobias JW, Kanai M, Shirakawa Y, Naomoto Y, Klein-Szanto AJ, Haase VH, Nakagawa H. Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis. 2010 Mar;31(3):427-34.   PMCID: PMC2832548 (available on 3/1/2010)
Rusthoven KE, Feigenberg SJ, Raben D, Kane M, Song JI, Nicolaou N, Mehra R, Burtness B, Ridge J, Swing R, Lango M, Cohen R, Jimeno A, Chen CH. INITIAL RESULTS OF A PHASE I DOSE-ESCALATION TRIAL OF CONCURRENT AND MAINTENANCE ERLOTINIB AND REIRRADIATION FOR RECURRENT AND NEW PRIMARY HEAD-AND-NECK CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Nov;78(4):1020-5.   PMCID: not NIH funded
Fu J, Zhang JR, Jin F, Patchefsky J, Braunewell KH, Klein-Szanto AJ. Promoter Regulation of the Visinin-like Subfamily of Neuronal Calcium Sensor Proteins by Nuclear Respiratory Factor-1. Journal of Biological Chemistry. 2009 Oct;284(40):27577-86.   PMCID: PMC2785686
Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. ONCOGENE. 2006 Mar;25(11):1602-11.
Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS, Forastiere A, Weber RS. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14. Journal of Clinical Oncology. 2005 May;23(13):3008-15.
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study. Journal of Clinical Oncology. 2005 Dec;23(34):8646-54.
Raimondi S, Boffetta P, Anttila S, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Dragani TA, Garte S, Gsur A, Haidinger G, Hirvonen A, Ingelman-Sundberg M, Kalina I, Lan Q, Leoni VP, Le Marchand L, London SJ, Neri M, Povey AC, Rannug A, Reszka E, Ryberg D, Risch A, Romkes M, Ruano-Ravina A, Schoket B, Spinola M, Sugimura H, Wu XF, Taioli E. Metabolic gene polymorphisms and lung cancer risk in non-smokers - An update of the GSEC study. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis. 2005 Dec 30;592(1-2):45-57.
Siegelmann-Danieli N, Ben-Izhack O, Hanlon A, Ridge JA, Stein ME, Khandelwal V, Langer CJ. P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori. 2005 Jul;91(4):346-50.
Sauter ER, Yeo UC, von Stemm A, Zhu WZ, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Research. 2002 Jun;62(11):3200-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term squamous-cell carcinoma

squamous-cell carcinoma chemotherapy positron-emission-tomography chemoradiotherapy colorectal-cancer randomized-trial therapy expression phase-ii trial radiotherapy surgery uterine cervix NCCN Guidelines junction high-grade dysplasia intensity-modulated radiotherapy chemoradiation paclitaxel Head-and-neck cancer long-term survival NCCN Clinical Practice Guidelines nasopharyngeal carcinoma cancer overexpression Chemotherapy esophagogastric growth-factor receptor combination cooperative-oncology-group radiation-therapy Reirradiation Radiation therapy mutations gastroesophageal junction breast-cancer accelerated fractionation chain-reaction assay concurrent chemotherapy poorly phase-ii gstm1 genotypes unknown primary site fdg-pet factor receptor esophageal cancer sided definitive chemoradiotherapy Elderly tumor-suppressor gene formulation dose fractionation plus cetuximab gene oropharynx inducible factor-1-alpha k-ras activation cervical-cancer preoperative chemoradiation epidemiology pooled analysis-genetic susceptibility lung-cancer phase-iii trial group rtog salvage surgery dna adduct levels deprivation-induced apoptosis concurrent chemoradiotherapy minimally invasive esophagectomy chromosome 11q13 amplification carcinoma of unknown primary trimodality oncology-group chemoradiation therapy gastric-cancer metastatic Salvage surgery dependent kinase inhibitor up-regulation Cisplatin cancer-research-network Neoadjuvant therapy epidermal-growth-factor multidisciplinary care class-mu prostate-cancer codon 72 polymorphism monoclonal-antibody c225 defects Multimodality therapy Esophageal carcinoma-Neoadjuvant therapy-Chemotherapy-Radiotherapy-Gastroesophageal junction (GEJ)-Esophageal cancer-Treatment Salvage cancer-cells biologic therapy transcriptional activity pathological response MDM2 waf1-polymorphism-apoptosis n-acetyltransferase esophageal fmr1 promoter familial breast-cancer c225 P53 immunohistochemistry-smoking-squamous cell carcinoma-tongue combination-chemotherapy regimens growth-factor s-transferase m1 perfusion germ-line polymorphisms Chemoradiation prostaglandin-e synthase-1 neck-cancer biogenesis 2-stage designs altered fractionation blockade 2009 doloff da-j natl compr canc s2-v7-p1 organ dose radiation gstt1 polymorphisms african-americans advanced head Cervical cancer survival mammalian-cells tumor response vilip-1 prognostic-factors esophageal epithelial-cells arbeitsgemeinschaft internistische onkologie multicenter oncology group rtog binding protein 3-dimensional conformal radiotherapy differentiated adenocarcinoma neoadjuvant chemoradiation preservation resection treatment strategy carcinoma factor-a esophagectomy albumin-bound p21 p53 Appropriateness criteria 1987 arlson me-v40-p373 mitochondrial transcription factor fluorouracil 2nd primary head neoadjuvant chemoradiotherapy Cetuximab Esophageal cancer primary tumors postoperative reirradiation
Last updated on Sunday, July 05, 2020